Avid Bioservices Inc (CDMO)

[semper]

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nn3lzn/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2015" report to their offering.

“Rectal Cancer - Pipeline Review, H1 2015”

This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

AbbVie Inc.
Apogenix GmbH
Cerulean Pharma, Inc.
GlaxoSmithKline plc
Hanwha Chemical Corporation
Incuron, LLC
Karyopharm Therapeutics, Inc.
Nanobiotix
Peregrine Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Drug Profiles

APG-350
bavituximab
CRLX-101
ganetespib
GSK-2256098
HD-204
mepacrine
NBTX-IV
NBTXR-3
selinexor
veliparib
ziv-aflibercept (recombinant)

http://www.businesswire.com/news/home/20150520005564/en/Research-Markets-Global-Rectal-Cancer-Pipeline-Report#.VZmC5flViko